Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iofolastat SCHEMBL9903616 | 1.00 | FOLH1 (1.00) | FOLH1 | |
| Iofolastat SCHEMBL20496027 | 1.00 | FOLH1 (1.00) | FOLH1 | |
| Iofolastat SCHEMBL18493678 | 1.00 | FOLH1 (1.00) | FOLH1 | |
| SCHEMBL11984373 | 0.92 | FOLH1 (0.85) | FOLH1 | |
| SCHEMBL11977609 | 0.91 | FOLH1 (0.84) | FOLH1 | |
| SCHEMBL11977607 | 0.91 | FOLH1 (0.84) | FOLH1 | |
| SCHEMBL13287546 | 0.91 | FOLH1 (0.83) | FOLH1 | |
| SCHEMBL22466370 | 0.89 | FOLH1 (0.79) | FOLH1 | |
| SCHEMBL22466369 | 0.89 | FOLH1 (0.79) | FOLH1 | |
| SCHEMBL4336024 | 0.89 | FOLH1 (1.00) | FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240016813-A1 | METHODS OF TREATING SYMPTOMS OF CORONAVIRUS INFECTION | Accencio LLC | 2024-01-18 | — | — | US | disclosed |
| WO-2021202376-A1 | METHOD FOR BLOCKING UPTAKE OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA)-TARGETED RADIONUCLIDES BY EXOCRINE ORGANS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-10-07 | — | — | WO | disclosed |
| US-11027029-B2 | Peptide thiourea derivative, radioisotope labeled compound containing same, and pharmaceutical composition containing same as active ingredient for treating or diagnosing prostate cancer | CELLBION CO., LTD (KR) | 2021-06-08 | — | — | US | disclosed |
| EP-3375787-B1 | PEPTIDE THIOUREA DERIVATIVE, RADIOISOTOPE LABELED COMPOUND CONTAINING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR TREATING OR DIAGNOSING PROSTATE CANCER | CELLBION CO LTD (KR) | 2019-05-08 | — | — | EP | disclosed |
| US-20180339071-A1 | PEPTIDE THIOUREA DERIVATIVE, RADIOISOTOPE LABELED COMPOUND CONTAINING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR TREATING OR DIAGNOSING PROSTATE CANCER | CELLBION CO., LTD. (KR) | 2018-11-29 | — | — | US | disclosed |
| EP-3375787-A1 | PEPTIDE THIOUREA DERIVATIVE, RADIOISOTOPE LABELED COMPOUND CONTAINING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR TREATING OR DIAGNOSING PROSTATE CANCER | Cellbion Co., Ltd. (KR) | 2018-09-19 | — | — | EP | disclosed |
| US-9878980-B2 | Heterodimers of glutamic acid | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20170044098-A1 | Heterodimers of Glutamic Acid | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2017-02-16 | — | — | US | disclosed |
| US-9433594-B2 | Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2016-09-06 | — | — | US | disclosed |
| US-20160222036-A1 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2016-08-04 | — | — | US | disclosed |
| EP-2706057-B1 | Bis(imidazolyl)compounds and radionuclide complexes | MOLECULAR INSIGHT PHARM INC (US) | 2016-04-20 | — | — | EP | disclosed |
| US-8962799-B2 | Technetium—and rhenium-bis(heteroaryl) complexes and methods of use thereof | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-20140341805-A1 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2014-11-20 | — | — | US | disclosed |
| US-8840865-B2 | Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-20140179902-A1 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| EP-2706057-A1 | Bis(imidazolyl)compounds and radionuclide complexes | Molecular Insight Pharmaceuticals, Inc. (US) | 2014-03-12 | — | — | EP | disclosed |
| US-8562945-B2 | Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2013-10-22 | — | — | US | disclosed |
| EP-2373621-A2 | TECHNETIUM-AND RHENIUM-BIS(HETEROARYL)COMPLEXES AND METHODS OF USE THEREOF | Molecular Insight Pharmaceuticals, Inc. (US) | 2011-10-12 | — | — | EP | disclosed |
| US-20100183509-A1 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2010-07-22 | — | — | US | disclosed |
| WO-2010065899-A2 | TECHNETIUM-AND RHENIUM-BIS(HETEROARYL)COMPLEXES AND METHODS OF USE THEREOF | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140341805-A1 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF | RAB35, SLC39A14, SLC39A3 | FOLH1 283/4885 |
| US-20180339071-A1 | PEPTIDE THIOUREA DERIVATIVE, RADIOISOTOPE LABELED COMPOUND CONTAINING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR TREATING OR DIAGNOSING PROSTATE CANCER | FOLH1, KLK3, SLC10A2 | FOLH1 1/4885 |
| US-20140179902-A1 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF | SSTR5, SSTR3, SSTR4 | FOLH1 216/4885 |
| US-20240016813-A1 | METHODS OF TREATING SYMPTOMS OF CORONAVIRUS INFECTION | ACE2, ACE, TMPRSS2 | FOLH1 181/4885 |
| US-20160222036-A1 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF | RAB35, SLC39A14, SLC39A3 | FOLH1 283/4885 |
| US-20170044098-A1 | Heterodimers of Glutamic Acid | DDO, GLUL, ASNS | FOLH1 5/4885 |
| US-20100183509-A1 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF | SSTR5, SSTR3, SSTR4 | FOLH1 216/4885 |
| US-11027029-B2 | Peptide thiourea derivative, radioisotope labeled compound containing same, and pharmaceutical composition containing same as active ingredient for treating or diagnosing prostate cancer | FOLH1, KLK3, SLC10A2 | FOLH1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.